One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Vaccines Market

[ 英語タイトル ] Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023


Product Code : MNMHC00110137
Survey : MarketsandMarkets
Publish On : March, 2021
Number of Pages : 185
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5650 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

“Global vaccines market projected to grow at a CAGR of 6.7%”
The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development.


“Monovalent vaccines segment expected to hold the largest share of the market in 2018.”
Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.
“Pneumococcal disease segment is expected to hold largest share of the market in 2018”
Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share of the vaccines market in 2018. The large share of this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal diseases.
“Asia to witness high growth during the forecast period”
In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 36%; Tier 2 - 41%; Tier 3 - 23%.
• By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
• By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
• By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report
• GlaxoSmithKline plc (US)
• Pfizer, Inc. (US)
• Merck & Co., Inc. (US)
• Sanofi Pasteur SA (France)
• CSL Limited (Australia)
• Emergent BioSolutions, Inc. (US)
• Johnson & Johnson (US)
• MedImmune, LLC (US)
• Astellas Pharma Inc. (Japan)
• Serum Institute of India (India)
• Bavarian Nordic (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Biological E (India)
• Panacea Biotec (India)

Research Coverage:
The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKET COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DESIGN 22
2.1.1 SECONDARY DATA 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY DATA 23
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 29
2.4 MARKET SHARE ESTIMATION 30
2.5 ASSUMPTIONS FOR THE STUDY 30
3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 35
4.1 OVERVIEW OF THE VACCINES MARKET 35
4.2 VACCINES MARKET, BY TYPE, 2018–2023 36
4.3 VACCINES MARKET, BY END USER, 2018 VS. 2023 (USD BILLION) 36
4.4 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY 37
4.5 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 VS. 2023 (USD BILLION) 38
4.6 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 38

5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 High prevalence of infectious diseases 40
5.2.1.2 Rising focus on immunization programs 40
5.2.1.3 Growing government support for vaccine development 41
5.2.1.4 Increasing company initiatives to enhance vaccine R&D 42
5.2.2 RESTRAINTS 42
5.2.2.1 High cost of vaccine development 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 High growth prospects in emerging markets 42
5.2.3.2 Focus on therapeutic vaccines 43
5.2.3.3 Use of adjuvants in vaccines 43
5.2.4 CHALLENGES 44
5.2.4.1 Inadequate access to vaccines 44
5.2.4.2 Product recalls 45
6 INDUSTRY INSIGHTS 46
6.1 REGULATORY LANDSCAPE 46
6.1.1 NORTH AMERICA 47
6.1.2 EUROPE 47
6.1.3 ASIA 48
6.1.4 ROW 48
6.2 KEY PIPELINE PRODUCTS 49
6.3 NEW VACCINE OPPORTUNITIES 50
6.3.1 HIV 50
6.3.1.1 HIV vaccine: product pipeline 50
6.3.1.2 HIV vaccine: public-private initiatives 51
6.3.1.3 HIV vaccine: funding 51
6.3.2 MALARIA 53
6.3.2.1 Malaria vaccine: product pipeline 53
6.3.2.2 Malaria vaccine: public-private initiatives 54
6.3.3 ZIKA 54
6.3.3.1 Zika vaccine: product pipeline 54
6.3.3.2 Zika vaccine: public-private initiatives 55
6.3.3.3 Zika vaccine: funding 55
6.3.4 EBOLA 55
6.3.4.1 Ebola vaccine: product pipeline 55
6.3.4.2 Ebola vaccine: public-private initiatives 56
6.3.4.3 Ebola vaccine: funding 56
7 VACCINES MARKET, BY TECHNOLOGY 57
7.1 INTRODUCTION 58
7.2 CONJUGATE VACCINES 59
7.3 INACTIVATED AND SUBUNIT VACCINES 60
7.4 LIVE ATTENUATED VACCINES 61
7.5 RECOMBINANT VACCINES 62
7.6 TOXOID VACCINES 63
8 VACCINES MARKET, BY TYPE 65
8.1 INTRODUCTION 66
8.2 MONOVALENT VACCINES 67
8.3 MULTIVALENT VACCINES 68
9 VACCINES MARKET, BY DISEASE INDICATION 70
9.1 INTRODUCTION 71
9.2 PNEUMOCOCCAL DISEASE 73
9.3 DTP 74
9.4 INFLUENZA 75
9.5 HPV 76
9.6 MENINGOCOCCAL DISEASE 77
9.7 POLIO 79
9.8 ROTAVIRUS 80
9.9 HEPATITIS 81
9.10 MMR 82
9.11 VARICELLA 83
9.12 DENGUE 84
9.13 HERPES ZOSTER 85
9.14 OTHER DISEASE INDICATIONS 85
10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 87
10.1 INTRODUCTION 88
10.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 89
10.3 ORAL ADMINISTRATION 90
10.4 OTHER ROUTES OF ADMINISTRATION 90
11 VACCINES MARKET, BY PATIENT TYPE 92
11.1 INTRODUCTION 93
11.2 PEDIATRIC PATIENTS 94
11.3 ADULT PATIENTS 95

12 VACCINES MARKET, BY REGION 97
12.1 INTRODUCTION 98
12.2 NORTH AMERICA 98
12.2.1 US 102
12.2.2 CANADA 103
12.3 EUROPE 104
12.3.1 GERMANY 108
12.3.2 UK 109
12.3.3 FRANCE 110
12.3.4 ITALY 111
12.3.5 SPAIN 112
12.3.6 ROE 112
12.4 ASIA 114
12.4.1 JAPAN 118
12.4.2 CHINA 119
12.4.3 INDIA 120
12.4.4 REST OF ASIA (ROA) 121
12.5 REST OF THE WORLD (ROW) 122
13 COMPETITIVE LANDSCAPE 127
13.1 OVERVIEW 127
13.2 MARKET SHARE ANALYSIS 128
13.3 COMPETITIVE SITUATION AND TRENDS 130
13.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 130
13.3.2 PRODUCT LAUNCHES AND APPROVALS 131
13.3.3 ACQUISITIONS 131
13.3.4 EXPANSIONS 132

14 COMPANY PROFILES 133
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 PFIZER 133
14.2 GLAXOSMITHKLINE 137
14.3 MERCK 141
14.4 SANOFI PASTEUR 144
14.5 CSL LIMITED 148
14.6 EMERGENT BIOSOLUTIONS 151
14.7 JOHNSON & JOHNSON 154
14.8 MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA) 157
14.9 ASTELLAS PHARMA 159
14.10 SERUM INSTITUTE OF INDIA 161
14.11 BAVARIAN NORDIC 164
14.12 MITSUBISHI TANABE PHARMA CORPORATION 167
14.13 DAIICHI SANKYO COMPANY 170
14.14 PANACEA BIOTEC 173
14.15 BIOLOGICAL E 176
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
15 APPENDIX 178
15.1 DISCUSSION GUIDE 178
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 181
15.3 AVAILABLE CUSTOMIZATIONS 183
15.4 RELATED REPORTS 183
15.5 AUTHOR DETAILS 184

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+